Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606890 | 1.00 | SLC22A6 (0.43) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL10780877 | 0.84 | GPR84 (0.44) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL1895728 | 0.79 | SLC22A6 (0.48) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL3064786 | 0.79 | SLC22A6 (0.48) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL10774516 | 0.78 | GPR84 (0.61) | SLC22A6GPR84MAPTTSHRTDP1 | |
| SCHEMBL2510902 | 0.77 | SLC22A6 (0.46) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL10777996 | 0.77 | — | — | |
| SCHEMBL7752611 | 0.76 | — | — | |
| SCHEMBL4748392 | 0.75 | MME (0.44) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 | |
| SCHEMBL16600360 | 0.75 | SLC22A6 (0.43) | SLC22A6SMN1; SMN2GPR84MAPTGABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128213-A1 | Sixteen-membered macrolide compounds | KOSAN BIOSCIENCES, INC. | 2002-09-12 | — | — | US | disclosed |
| US-20020111317-A1 | Sixteen-membered macrolide compounds | KOSAN BIOSCIENCES, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002032916-A2 | SIXTEEN-MEMBERED MACROLIDE COMPOUNDS | KOSAN BIOSCIENCES, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111317-A1 | Sixteen-membered macrolide compounds | NOP2, NSUN3, MRPS23 | SLC22A6 2145/4885SMN1; SMN2 1841/4885GPR84 1452/4885 |
| US-20020128213-A1 | Sixteen-membered macrolide compounds | NOP2, NSUN3, MRPS23 | SLC22A6 2145/4885SMN1; SMN2 1841/4885GPR84 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.